Phadia Positions the Pharmaceutical Industry to Harness the Power of Personalized Medicine with the Introduction of Innovative Immune Response Diagnostics

Published: Mar 14, 2011

UPPSALA, Sweden & PORTAGE, Mich.--(BUSINESS WIRE)--While novel protein-based therapies have shown great promise for combating diseases like cancer, AIDS, and arthritis, they also present new challenges in drug development. All biopharmaceuticals have a risk of generating an immune response. This immunogenicity has the potential to impact safety and efficacy of the biopharmaceutical. A crucial component of understanding the immunogenicity is to characterize the capacity of the antibody response to neutralize the biopharmaceutical activity and any endogenous counterparts, which could impact the efficacy and safety of the biopharmaceutical. The use of technology to identify the right patient groups has the potential to speed accurate diagnosis, decrease side effects, and increase the likelihood that a medicine will work for an individual patient.

Back to news